Biomarkers in Neurodegenerative Diseases

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease

Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155

Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis

Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., et al. (1993) · Nature · doi:10.1038/362059a0 · Cited by 7,062

Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework

Biomarkers Definitions Working Group (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,771

Parkinson's disease: clinical features and diagnosis

Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806

Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease

Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B

Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496

The Human Plasma Proteome

Anderson, N. L., & Anderson, N. G. (2002) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r200007-mcp200 · Cited by 4,414

A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD

Renton, A. E., Majounie, E., Waite, A., Simón-Sánchez, J., Rollinson, S., Gibbs, J. R., Schymick, J. C., Laaksovirta, H., van Swieten, J. C., Myllykangas, L., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.010 · Cited by 4,409

Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268

Epidemiology of Parkinson's disease

de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110

Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease

Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051

Phases of Aβ-deposition in the human brain and its relevance for the development of AD

Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490

Candidate gene for the chromosome 1 familial Alzheimer’s disease locus

Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049

Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease

Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., et al. (1994) · Nature Genetics · doi:10.1038/ng0694-180 · Cited by 1,920

Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease

International Parkinson's Disease Genomics Consortium (IPDGC), Nalls, M. A., Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI), 23andMe, GenePD, NeuroGenetics Research Consortium (NGRC), Hussman Institute of Human Genomics (HIHG), Investigator, T. A. J. D., (CHARGE), C. F. H. A. A. R. I. G. E., North American Brain Expression Consortium (NABEC), et al. (2014) · Nature Genetics · doi:10.1038/ng.3043 · Cited by 1,895

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700

State of play in amyotrophic lateral sclerosis genetics

Renton, A. E., Chiò, A., & Traynor, B. J. (2013) · Nature Neuroscience · doi:10.1038/nn.3584 · Cited by 1,626

Genetics of Parkinson's DiseasePreprint

Klein, C., & Westenberger, A. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a008888 · Cited by 1,446

Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416

Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury

Reaume, A. G., Elliott, J. L., Hoffman, E. K., Kowall, N. W., Ferrante, R. J., Siwek, D. F., Wilcox, H. M., Flood, D. G., Beal, M. F., Brown, R. H., et al. (1996) · Nature Genetics · doi:10.1038/ng0596-43 · Cited by 1,285

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans

Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246

PET Imaging of Tau Deposition in the Aging Human Brain

Schöll, M., Lockhart, S. N., Schonhaut, D. R., O’Neil, J. P., Janabi, M., Ossenkoppele, R., Baker, S. L., Vogel, J. W., Faria, J., Schwimmer, H. D., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.01.028 · Cited by 1,214

Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study

Majounie, E., Renton, A. E., Mok, K., Dopper, E. G., Waite, A., Rollinson, S., Chiò, A., Restagno, G., Nicolaou, N., Simon-Sanchez, J., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70043-1 · Cited by 1,210

CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment

Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176

Unconventional Translation of C9ORF72 GGGGCC Expansion Generates Insoluble Polypeptides Specific to c9FTD/ALS

Ash, P. E. A., Bieniek, K. F., Gendron, T. F., Caulfield, T. R., Lin, W.-L., DeJesus‐Hernandez, M., van Blitterswijk, M., Jansen‐West, K. R., Paul, J. W., Rademakers, R., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.02.004 · Cited by 1,127

Use of Florbetapir-PET for Imaging β-Amyloid Pathology

Clark, C. M. (2011) · JAMA · doi:10.1001/jama.2010.2008 · Cited by 1,117

The Human Plasma Proteome

Anderson, N. L., Polanski, M., Pieper, R., Gatlin, T., Tirumalai, R. S., Conrads, T. P., Veenstra, T. D., Adkins, J., Pounds, J. G., Fagan, R. J., et al. (2004) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m300127-mcp200 · Cited by 1,004

Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging

Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.007 · Cited by 986

Tau positron emission tomographic imaging in aging and early Alzheimer disease

Johnson, K. A., Schultz, A., Betensky, R. A., Becker, J. A., Sepulcre, J., Rentz, D., Mormino, E., Chhatwal, J., Amariglio, R., Papp, K., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24546 · Cited by 986

Synthesis and Evaluation of 11C-Labeled 6-Substituted 2-Arylbenzothiazoles as Amyloid Imaging Agents

Mathis, C. A., Wang, Y., Holt, D. P., Huang, G.-F., Debnath, M. L., & Klunk, W. E. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030026b · Cited by 976

Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case‐control study

Fiandaca, M. S., Kapogiannis, D., Mapstone, M., Boxer, A., Eitan, E., Schwartz, J. B., Abner, E. L., Petersen, R. C., Federoff, H. J., Miller, B. L., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.06.008 · Cited by 959

Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease

Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., et al. (2008) · Brain · doi:10.1093/brain/awn016 · Cited by 933

Cerebrospinal Fluid tau/β-Amyloid42 Ratio as a Prediction of Cognitive Decline in Nondemented Older Adults

Fagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897

RNA Toxicity from the ALS/FTD C9ORF72 Expansion Is Mitigated by Antisense Intervention

Donnelly, C. J., Zhang, P.-W., Pham, J. T., Haeusler, A. R., Mistry, N. A., Vidensky, S., Daley, E. L., Poth, E. M., Hoover, B., Fines, D. M., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.10.015 · Cited by 877

Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease

Höck, C., Konietzko, U., Streffer, J. R., Tracy, J., Signorell, A., Müller-Tillmanns, B., Lemke, U., Henke, K., Moritz, E., Garcia, E., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00294-0 · Cited by 786

Astrocytes from familial and sporadic ALS patients are toxic to motor neurons

Haidet-Phillips, A. M., Hester, M. E., Miranda, C. J., Meyer, K., Braun, L., Frakes, A., Song, S., Likhite, S., Murtha, M. J., Foust, K. D., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1957 · Cited by 782

Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls

Maruyama, M., Shimada, H., Suhara, T., Shinotoh, H., Ji, B., Maeda, J., Zhang, M.-R., Trojanowski, J. Q., Lee, V. M.-Y., Ono, M., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.07.037 · Cited by 760

Hippocampal and entorhinal atrophy in mild cognitive impairment

Devanand, D. P., Pradhaban, G., Liu, X., Khandji, A., Santi, S. D., Segal, S., Rusinek, H., Pelton, G. H., Honig, L. S., Mayeux, R. P., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000256697.20968.d7 · Cited by 749

PET imaging of amyloid deposition in patients with mild cognitive impairment

Forsberg, A., Engler, H., Almkvist, O., Blomquist, G., Hagman, G., Wall, A. E., Ringheim, A., Långström, B., & Nordberg, A. K. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.03.029 · Cited by 725

Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's disease

El‐Agnaf, O. M. A., Salem, S. A., Paleologou, K. E., Curran, M. D., Gibson, M. J., Court, J. A., Schlossmacher, M. G., & Allsop, D. (2006) · The FASEB Journal · doi:10.1096/fj.03-1449com · Cited by 715

In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18 F-AV-45 (Flobetapir F 18)

Wong, D. F., Rosenberg, P. B., Zhou, Y., Kumar, A., Raymont, V., Ravert, H. T., Dannals, R. F., Nandi, A., Brašić, J. R., Ye, W., et al. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.069088 · Cited by 684

Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F18]-T808

Chien, D. T., Szardenings, A. K., Bahri, S., Walsh, J. C., Mu, F., Xia, C. A., Shankle, W. R., Lerner, A. J., Su, M., Elizarov, A. M., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130098 · Cited by 683

Targeting RNA Foci in iPSC-Derived Motor Neurons from ALS Patients with a C9ORF72 Repeat Expansion

Sareen, D., O’Rourke, J. G., Meera, P., Muhammad, A. K. M. G., Grant, S., Simpkinson, M., Bell, S., Carmona, S., Ornelas, L., Sahabian, A., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007529 · Cited by 670

18 F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial

Vandenberghe, R. R., Laere, K. V., Ivanoiu, A., Salmon, É., Bastin, C., Triau, E., Hasselbalch, S. G., Law, I. G., Andersen, A., Kørner, A., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22068 · Cited by 664

Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807

Chien, D. T., Bahri, S., Szardenings, A. K., Walsh, J. C., Mu, F., Su, M.-Y., Shankle, W. R., Elizarov, A., & Kolb, H. C. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-122059 · Cited by 651

α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study

Mollenhauer, B., Locascio, J. J., Schulz‐Schaeffer, W., Sixel‐Döring, F., Trenkwalder, C., & Schlossmacher, M. G. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70014-x · Cited by 636

ALS motor phenotype heterogeneity, focality, and spread

Ravits, J., & Spada, A. R. L. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b6bbbd · Cited by 629

Systematic review of incidence studies of Parkinson's disease

Twelves, D., Perkins, K. S. M., & Counsell, C. E. (2002) · Movement Disorders · doi:10.1002/mds.10305 · Cited by 619

DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease

Hong, Z., Shi, M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J., Zabetian, C. P., Leverenz, J. B., Baird, G., et al. (2010) · Brain · doi:10.1093/brain/awq008 · Cited by 615

FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease

Foster, N. L., Heidebrink, J. L., Clark, C. M., Jagust, W. J., Arnold, S. E., Barbas, N. R., DeCarli, C. S., Scott Turner, R., Koeppe, R. A., Higdon, R., et al. (2007) · Brain · doi:10.1093/brain/awm177 · Cited by 608

Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis

Lu, C.-H., Macdonald-Wallis, C., Gray, E., Pearce, N., Petzold, A., Norgren, N., Giovannoni, G., Fratta, P., Sidle, K., Fish, M., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001642 · Cited by 563

Biomarkers and surrogate endpoints in clinical trials

Fleming, T. R., & Powers, J. H. (2012) · Statistics in Medicine · doi:10.1002/sim.5403 · Cited by 559

Conversion of Mild Cognitive Impairment to Alzheimer Disease Predicted by Hippocampal Atrophy Maps

Apostolova, L. G., Dutton, R. A., Dinov, I. D., Hayashi, K. M., Toga, A. W., Cummings, J. L., & Thompson, P. M. (2006) · Archives of Neurology · doi:10.1001/archneur.63.5.693 · Cited by 553

Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease

Tokuda, T., Qureshi, M. M., Ardah, M. T., Varghese, S., Shehab, S. A. S., Kasai, T., Ishigami, N., Tamaoka, A., Nakagawa, M., & El‐Agnaf, O. M. A. (2010) · Neurology · doi:10.1212/wnl.0b013e3181fd613b · Cited by 531

Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model

Ralph, G. S., Radcliffe, P. A., Day, D. M., Carthy, J. M., Leroux, M. A., Lee, D. C. P., Wong, L., Bilsland, L. G., Greensmith, L., Kingsman, S. M., et al. (2005) · Nature Medicine · doi:10.1038/nm1205 · Cited by 507

Cerebrospinal fluid protein biomarkers for Alzheimer’s disease

Blennow, K. (2004) · Neurotherapeutics · doi:10.1602/neurorx.1.2.213 · Cited by 500

Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases

Gaiottino, J., Norgren, N., Dobson, R., Topping, J. H., Nissim, A., Malaspina, A., Bestwick, J. P., Monsch, A. U., Regeniter, A., Lindberg, R. L. P., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075091 · Cited by 493

Locus‐specific mutation databases for neurodegenerative brain diseases

Cruts, M., Theuns, J., & Broeckhoven, C. V. (2012) · Human Mutation · doi:10.1002/humu.22117 · Cited by 490

Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression

Zetterberg, H., Skillbäck, T., Mattsson, N., Trojanowski, J. Q., Portelius, E., Shaw, L. M., Weiner, M. W., Blennow, K., & Initiative, F. T. A. D. N. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2015.3037 · Cited by 487

Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study

Byrne, S., Elamin, M., Bede, P., Shatunov, A., Walsh, C., Corr, B., Heverin, M., Jordan, N., Kenna, K. P., Lynch, C. M., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70014-5 · Cited by 483

Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins

Mori, K., Arzberger, T., Grässer, F. A., Gijselinck, I., May, S., Rentzsch, K., Weng, S., Schludi, M. H., van der Zee, J., Cruts, M., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1189-3 · Cited by 482

Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS

Butovsky, O., Siddiqui, S., Gabriely, G., Lanser, A. J., Dake, B., Murugaiyan, G., Doykan, C. E., Wu, P. M., Gali, R. R., Iyer, L. K., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62636 · Cited by 481

Regional Cerebral Metabolic Alterations in Dementia of the Alzheimer Type

Friedland, R. P., Budinger, T. F., Ganz, E., Yano, Y., Mathis, C. A., Koss, B., Ober, B. A., Huesman, R. H., & Derenzo, S. (1983) · Journal of Computer Assisted Tomography · doi:10.1097/00004728-198308000-00003 · Cited by 468

Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS

Raoul, C., Abbas‐Terki, T., Bensadoun, J., Guillot, S., Haase, G., Szulc, J., Henderson, C. E., & Aebischer, P. (2005) · Nature Medicine · doi:10.1038/nm1207 · Cited by 464

Biomarkers in amyotrophic lateral sclerosis

Turner, M. R., Kiernan, M. C., Leigh, P. N., & Talbot, K. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70293-x · Cited by 440

Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis

Beers, D. R., Henkel-Tigges, J., Zhao, W., Wang, J., Huang, A., Wen, S., Liao, B., & Appel, S. H. (2011) · Brain · doi:10.1093/brain/awr074 · Cited by 439

FDG PET in the differential diagnosis of parkinsonian disorders

Eckert, T., Barnes, A., DHAWAN, V. M., Frucht, S. J., Gordon, M. F., Feigin, A., & Eidelberg, D. (2005) · NeuroImage · doi:10.1016/j.neuroimage.2005.03.012 · Cited by 418

Plasma Urate and Risk of Parkinson's Disease

Weisskopf, M. G., O’Reilly, É. J., Chen, H., Schwarzschild, M. A., & Ascherio, A. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm127 · Cited by 395

T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS

Chiu, I. M., Chen, A., Zheng, Y., Kosaras, B., Tsiftsoglou, S. A., Vartanian, T. K., Brown, R. H., & Carroll, M. C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804610105 · Cited by 380

Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease

Palmqvist, S., Zetterberg, H., Mattsson, N., Johansson, P., Initiative, F. T. A. D. N., Minthon, L., Blennow, K., Olsson, M., For the Swedish BioFINDER study group, Hansson, O., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001991 · Cited by 375

Relationship between atrophy and β‐amyloid deposition in Alzheimer disease

Chételat, G., Villemagne, V. L., Bourgeat, P., Pike, K. E., Jones, G., Ames, D., Ellis, K. A., Szoeke, C., Martins, R. N., O'Keefe, G. J., et al. (2010) · Annals of Neurology · doi:10.1002/ana.21955 · Cited by 373

Discovery of a Biomarker and Lead Small Molecules to Target r(GGGGCC)-Associated Defects in c9FTD/ALS

Su, Z., Zhang, Y., Gendron, T. F., Bauer, P. O., Chew, J., Yang, W.-Y., Fostvedt, E., Jansen‐West, K. R., Belzil, V., Desaro, P., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.07.041 · Cited by 365

Using Positron Emission Tomography and Florbetapir F 18 to Image Cortical Amyloid in Patients With Mild Cognitive Impairment or Dementia Due to Alzheimer Disease

Fleisher, A. S. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.150 · Cited by 364

The resolution of neuroinflammation in neurodegeneration: leukocyte recruitment via the choroid plexus

Schwartz, M., & Baruch, K. (2014) · The EMBO Journal · doi:10.1002/embj.201386609 · Cited by 349

2014 Update of the Alzheimer’s Disease Neuroimaging Initiative: A review of papers published since its inception

Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Cedarbaum, J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.11.001 · Cited by 348

MCI conversion to dementia and the APOE genotype

Mosconi, L., Perani, D., Sorbi, S., Herholz, K., Nacmias, B., Holthoff‐Detto, V., Salmon, É., Baron, J., Cristofaro, M. T. D., Padovani, A., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000147469.18313.3b · Cited by 347

Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report.

Bacskai, B. J., Frosch, M. P., Freeman, S. H., Raymond, S. B., Augustinack, J. C., Johnson, K. A., Irizarry, M. C., Klunk, W. E., Mathis, C. A., DeKosky, S. T., et al. (2007) · PubMed · doi:10.1001/archneur.64.3.431 · Cited by 341

18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease

Harada, R., Okamura, N., Furumoto, S., Furukawa, K., Ishiki, A., Tomita, N., Tago, T., Hiraoka, K., Watanuki, S., Shidahara, M., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.164848 · Cited by 330

Heterogeneity of Brain Glucose Metabolism in Mild Cognitive Impairment and Clinical Progression to Alzheimer Disease

Anchisi, D., Borroni, B., Franceschi, M., Kerrouche, N., Kalbe, E., Beuthien-Beumann, B., Cappa, S. F., Lenz, O., Lüdecke, S., Marcone, A., et al. (2005) · Archives of Neurology · doi:10.1001/archneur.62.11.1728 · Cited by 320

Intravenous immunoglobulins containing antibodies against -amyloid for the treatment of Alzheimer's disease

Dodel, R. C. (2004) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.033399 · Cited by 319

Modeling ALS with iPSCs reveals that mutant SOD1 misregulates neurofilament balance in motor neurons

Chen, H., Qian, K., Du, Z., Cao, J., Petersen, A., Liu, H., Blackbourn, L. W., Huang, C.-L., Errigo, A., Yin, Y., et al. (2014) · Cell stem cell · doi:10.1016/j.stem.2014.02.004 · Cited by 318

EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans

Hoecke, A. V., Schoonaert, L., Lemmens, R., Timmers, M., Staats, K. A., Laird, A. S., Peeters, E., Philips, T., Goris, A., Dubois, B., et al. (2012) · Nature Medicine · doi:10.1038/nm.2901 · Cited by 313

Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects

Trojanowski, J. Q., Vandeerstichele, H., Korecka, M., Clark, C. M., Aisen, P. S. S., Petersen, R. C., Blennow, K., Soares, H. D., Simon, A. J., Lewczuk, P., et al. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.03.008 · Cited by 309

Serum Urate as a Predictor of Clinical and Radiographic Progression in Parkinson Disease

Schwarzschild, M. A. (2008) · Archives of Neurology · doi:10.1001/archneur.2008.65.6.nct70003 · Cited by 309

Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers

Initiative, T. A. D. N., Landau, S. M., Thomas, B. A., Thurfjell, L., Schmidt, M. E., Margolin, R. A., Mintun, M. A., Pontecorvo, M. J., Baker, S. L., & Jagust, W. J. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2753-3 · Cited by 306

What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?

Jagust, W. J., Reed, B., Mungas, D., Ellis, W. G., & DeCarli, C. S. (2007) · Neurology · doi:10.1212/01.wnl.0000269790.05105.16 · Cited by 303

PIB is a non-specific imaging marker of amyloid-beta (A ) peptide-related cerebral amyloidosis

Lockhart, A., Lamb, J. R., Osredkar, T., Sue, L. I., Joyce, J. N., Ye, L., Libri, V., Leppert, D., & Beach, T. G. (2007) · Brain · doi:10.1093/brain/awm191 · Cited by 302

Serum uric acid levels and the risk of Parkinson disease

de Lau, L. M. L., Koudstaal, P. J., Albert Hofman, D., & Breteler, M. M. B. (2005) · Annals of Neurology · doi:10.1002/ana.20663 · Cited by 302

Exosomes: vesicular carriers for intercellular communication in neurodegenerative disorders

Schneider, A., & Simons, M. (2012) · Cell and Tissue Research · doi:10.1007/s00441-012-1428-2 · Cited by 301

Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI

Initiative, T. A. D. N., Shaw, L. M. J., Vanderstichele, H., Knapik-Czajka, M. E., Figurski, M., Coart, E., Blennow, K., Soares, H. D., Simon, A. J., Lewczuk, P., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0808-0 · Cited by 301

Serum levels of brain-derived neurotrophic factor correlate with motor impairment in Parkinson’s disease

Scalzo, P., Kümmer, A., Bretas, T. L., Cardoso, F., & Teixeira, A. L. (2010) · Journal of Neurology · doi:10.1007/s00415-009-5357-2 · Cited by 299

Mutant Copper-Zinc Superoxide Dismutase (SOD1) Induces Protein Secretion Pathway Alterations and Exosome Release in Astrocytes

Basso, M., Pozzi, S., Tortarolo, M., Fiordaliso, F., Bisighini, C., Pasetto, L., Spaltro, G., Lidonnici, D., Gensano, F., Battaglia, E., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.425066 · Cited by 295

Corpus callosum involvement is a consistent feature of amyotrophic lateral sclerosis

Filippini, N., Douaud, G., Mackay, C. E., Knight, S., Talbot, K., & Turner, M. R. (2010) · Neurology · doi:10.1212/wnl.0b013e3181fb84d1 · Cited by 280

Beta Amyloid in Alzheimer's Disease: Increased Deposition in Brain Is Reflected in Reduced Concentration in Cerebrospinal Fluid

Grimmer, T., Riemenschneider, M., Förstl, H., Henriksen, G., Klunk, W. E., Mathis, C. A., Shiga, T., Wester, H.-J., Kurz, A., & Drzezga, A. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.01.027 · Cited by 278

Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET.

Drzezga, A. E., Grimmer, T., Riemenschneider, M., Lautenschlager, N. T., Siebner, H. R., Alexopoulus, P., Minoshima, S., Schwaiger, M., & Kurz, A. (2005) · PubMed · Cited by 277

Biomarkers of Alzheimer disease in plasma

Irizarry, M. C. (2004) · NeuroRx · doi:10.1602/neurorx.1.2.226 · Cited by 273

Non-invasive assessment of Alzheimer’s disease neurofibrillary pathology using 18F-THK5105 PET

Okamura, N., Furumoto, S., Fodero‐Tavoletti, M. T., Mulligan, R. S., Harada, R., Yates, P. A., Pejoska, S., Kudo, Y., Masters, C. L., Yanai, K., et al. (2014) · Brain · doi:10.1093/brain/awu064 · Cited by 273

Axonal damage markers in cerebrospinal fluid are increased in ALS

Brettschneider, J., Petzold, A., Süßmuth, S. D., Ludolph, A. C., & Tumani, H. (2006) · Neurology · doi:10.1212/01.wnl.0000203120.85850.54 · Cited by 261

Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: A clinical and electrophysiological study

Schwingenschuh, P., Ruge, D., Edwards, M. J., Terranova, C., Katschnig, P., Carrillo, F., Silveira‐Moriyama, L., Schneider, S. A., Kägi, G., Palomar, F. J., et al. (2010) · Movement Disorders · doi:10.1002/mds.23019 · Cited by 248

Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls

Morra, J. H., Tu, Z., Apostolova, L. G., Green, A. E., Avedissian, C., Madsen, S. K., Parikshak, N., Toga, A. W., Jack, C. R., Schuff, N. W., et al. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2008.10.043 · Cited by 244

The plasma alpha-synuclein levels in patients with Parkinson’s disease and multiple system atrophy

Lee, P. H., Lee, G., Park, H. J., Bang, O. Y., Joo, I. S., & Huh, K. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-005-0427-9 · Cited by 242

Structural Brain Changes in Parkinson Disease With Dementia

Summerfield, C., Junqué, C., TOLOSA, E. S., Salgado‐Pineda, P., Gómez‐Ansón, B., Martı́, M. J., Pástor, P., Ramírez‐Ruiz, B., & Mercader, J. (2005) · Archives of Neurology · doi:10.1001/archneur.62.2.281 · Cited by 240

CSF biomarkers and clinical progression of Parkinson disease

Hall, S., Surova, Y., Öhrfelt, A., Zetterberg, H., Lindqvist, D., & Hansson, O. (2014) · Neurology · doi:10.1212/wnl.0000000000001098 · Cited by 236

Test–Retest reliability of the Unified Parkinson's Disease Rating Scale in patients with early Parkinson's disease: Results from a multicenter clinical trial

Siderowf, A. D., McDermott, M., Kieburtz, K. D., Blindauer, K. A., Plumb, S., Shoulson, I., & the Parkinson Study Group (2002) · Movement Disorders · doi:10.1002/mds.10011 · Cited by 234

Quantitative analysis and clinico-pathological correlations of different dipeptide repeat protein pathologies in C9ORF72 mutation carriers

Mackenzie, I. R. A., Frick, P., Grässer, F. A., Gendron, T. F., Petrucelli, L., Cashman, N. R., Edbauer, D., Kremmer, E., Prudlo, J., Troost, D., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1476-2 · Cited by 231

Cerebrospinal Fluid Biomarkers and Rate of Cognitive Decline in Very Mild Dementia of the Alzheimer Type

Snider, B. J., Fagan, A. M., Roe, C. M., Shah, A. R., Grant, E., Xiong, C., Morris, J. C., & Holtzman, D. M. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.55 · Cited by 229

Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: Assessed with [11C]-PBR28

Zürcher, N. R., Loggia, M. L., Lawson, R., Chonde, D. B., Izquierdo-Garcia, D., Yasek, J. E., Akeju, O., Catana, C., Rosen, B. R., Cudkowicz, M. E., et al. (2015) · NeuroImage: Clinical · doi:10.1016/j.nicl.2015.01.009 · Cited by 226

Brain Volume Decline in Aging

Fotenos, A. F., Mintun, M. A., Snyder, A. Z., Morris, J. C., & Buckner, R. L. (2008) · Archives of Neurology · doi:10.1001/archneurol.2007.27 · Cited by 226

Cerebrospinal Fluid Tau and β-Amyloid 42 Proteins Identify Alzheimer Disease in Subjects With Mild Cognitive Impairment

Riemenschneider, M. J., Lautenschlager, N. T., Wagenpfeil, S., Diehl, J., Drzezga, A. E., & Kurz, A. (2002) · Archives of Neurology · doi:10.1001/archneur.59.11.1729 · Cited by 218

Early detection of Alzheimer's disease using PiB and FDG PET

Cohen, A. D., & Klunk, W. E. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.05.001 · Cited by 216

Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis

Kühle, J., Lindberg, R. L. P., Regeniter, A., Mehling, M., Steck, A., Kappos, L., & Czapliński, A. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02560.x · Cited by 214

Absence of Pittsburgh Compound B Detection of Cerebral Amyloid β in a Patient With Clinical, Cognitive, and Cerebrospinal Fluid Markers of Alzheimer Disease

Cairns, N. J., Ikonomović, M. D., Benzinger, T. L. S., Storandt, M., Fagan, A. M., Shah, A. R., Taylor‐Reinwald, L., Carter, D. R., Felton, A., Holtzman, D. M., et al. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.279 · Cited by 205

Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to β-amyloid peptide42

Maddalena, A., Papassotiropoulos, A., Müller-Tillmanns, B., Jung, H. H., Hegi, T., Nitsch, R. M., & Hock, C. (2003) · Archives of Neurology · doi:10.1001/archneur.60.9.1202 · Cited by 204

Plasma-Based Circulating MicroRNA Biomarkers for Parkinson's Disease

Khoo, S. K., Petillo, D., Kang, U. J., Resau, J. H., Berryhill, B., Linder, J., Forsgren, L., Neuman, L. A., & Tan, A. C. (2012) · Journal of Parkinson s Disease · doi:10.3233/jpd-012144 · Cited by 203

Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis

Pagani, M., Chiò, A., Valentini, M. C., Öberg, J., Nobili, F. M., Calvo, A., Moglia, C., Bertuzzo, D., Morbelli, S. D., Carli, F. D., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000792 · Cited by 202

Elevated Levels of α-Synuclein Oligomer in the Cerebrospinal Fluid of Drug-Naïve Patients with Parkinson's Disease

Park, M., Cheon, S., Bae, H.-R., Kim, S.-H., & Kim, J. W. (2011) · Journal of Clinical Neurology · doi:10.3988/jcn.2011.7.4.215 · Cited by 199

Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson’s disease

Waragai, M., Wei, J., Fujita, M., Nakai, M., Ho, G. J., Masliah, E., Akatsu, H., Yamada, T., & Hashimoto, M. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.05.011 · Cited by 197

Amyotrophic Lateral Sclerosis Outcome Measures and the Role of Albumin and Creatinine

Chiò, A., Calvo, A., Bovio, G., Canosa, A., Bertuzzo, D., Galmozzi, F., Cugnasco, P., Clerico, M., Mercanti, S. F. D., Bersano, E., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1129 · Cited by 195

Candidate Blood Proteome Markers of Alzheimer's Disease Onset and Progression: A Systematic Review and Replication Study

Kiddle, S. J., Sattlecker, M., Proitsi, P., Simmons, A., Westman, E., Bazenet, C. E., Nelson, S. K., Williams, S., Hodges, A., Johnston, C., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130380 · Cited by 190

Amyloid PET imaging in patients with mild cognitive impairment: A 2-year follow-up study

Koivunen, J., Scheinin, N., Virta, J. R., Aalto, S., Vahlberg, T., Någren, K., Helin, S., Parkkola, R., Viitanen, M., & Rinne, J. O. (2011) · Neurology · doi:10.1212/wnl.0b013e318212015e · Cited by 188

A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis

Mitchell, R. M., Freeman, W. M., Randazzo, W. T., Stephens, H., Beard, J. L., Simmons, Z., & Connor, J. R. (2008) · Neurology · doi:10.1212/01.wnl.0000333251.36681.a5 · Cited by 184

Angiotensin II Modulates BBB Permeability via Activation of the AT 1 Receptor in Brain Endothelial Cells

Fleegal, M. A., Doghu, S., & Banks, W. A. (2009) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2008.158 · Cited by 181

Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI

Toledo, J. B., Xie, S. X., Trojanowski, J. Q., & Shaw, L. M. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1151-4 · Cited by 180

Amyloid load and cerebral atrophy in Alzheimer's disease: An 11C‐PIB positron emission tomography study

Archer, H. A., Edison, P., Brooks, D. J., Barnes, J., Frost, C. D., Yeatman, T., Fox, N. C., & Rossor, M. N. (2006) · Annals of Neurology · doi:10.1002/ana.20889 · Cited by 179

Dissection of genetic factors associated with amyotrophic lateral sclerosis

Leblond, C. S., Kaneb, H., Dion, P. A., & Rouleau, G. A. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.04.013 · Cited by 175

Identification of TMEM230 mutations in familial Parkinson's disease

Deng, H., Shi, Y., Yang, Y., Ahmeti, K., Miller, N., Huang, C., Cheng, L., Zhai, H., Deng, S., Nuytemans, K., et al. (2016) · Nature Genetics · doi:10.1038/ng.3589 · Cited by 174

In vivo evaluation of a novel tau imaging tracer for Alzheimer’s disease

Villemagne, V. L., Furumoto, S., Fodero‐Tavoletti, M. T., Mulligan, R. S., Hodges, J. R., Harada, R., Yates, P. A., Piguet, O., Pejoska, S., Doré, V., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2681-7 · Cited by 173

The Role of Long Noncoding RNAs in Neurodegenerative Diseases

Wan, P., Su, W., & Zhuo, Y. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9793-6 · Cited by 173

A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease

Verwey, N. A., van der Flier, W. M., Blennow, K., Clark, C. M., Sokolow, S., Deyn, P. P. D., Galasko, D. R., Hampel, H. J., Hartmann, T., Kapaki, E., et al. (2009) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1258/acb.2009.008232 · Cited by 171

α-Synuclein Reactive Antibodies as Diagnostic Biomarkers in Blood Sera of Parkinson's Disease Patients

Yanamandra, K., Gruden, M. A., Casaite, V., Meskys, R., Forsgren, L., & Morozova-Roche, L. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018513 · Cited by 171

MicroRNAs in Parkinson's disease

Mouradian, M. M. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.046 · Cited by 168

Relationships between Disease Progression and Serum Levels of Lipid, Urate, Creatinine and Ferritin in Japanese Patients with Amyotrophic Lateral Sclerosis: A Cross-Sectional Study

Ikeda, K., Hirayama, T., Takazawa, T., Kawabe, K., & Iwasaki, Y. (2012) · Internal Medicine · doi:10.2169/internalmedicine.51.7465 · Cited by 167

In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia

Burack, M. A., Hartlein, J. M., Flores, H., Taylor-Reinwald, L., Perlmutter, J. S., & Cairns, N. J. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c7da8e · Cited by 165

Rodent models of amyotrophic lateral sclerosis

McGoldrick, P., Joyce, P. I., Fisher, E., & Greensmith, L. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.03.012 · Cited by 162

Plasma α-synuclein is decreased in subjects with Parkinson's disease

Li, Q., Mok, S. S., Laughton, K. M., McLean, C., Cappai, R., Masters, C. L., Culvenor, J. G., & Horne, M. K. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.12.006 · Cited by 161

Mass Spectrometry–Based Candidate Reference Measurement Procedure for Quantification of Amyloid-β in Cerebrospinal Fluid

Leinenbach, A., Pannee, J., Dülffer, T., Huber, A., Bittner, T., Andréasson, U., Gobom, J., Zetterberg, H., Kobold, U., Portelius, E., et al. (2014) · Clinical Chemistry · doi:10.1373/clinchem.2013.220392 · Cited by 158

In VitroCharacterization of Pittsburgh Compound-B Binding to Lewy Bodies

Fodero‐Tavoletti, M. T., Smith, D. P., McLean, C., Adlard, P. A., Barnham, K. J., Foster, L. E., Leone, L., Perez, K. A., Cortés, M., Culvenor, J. G., et al. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0630-07.2007 · Cited by 157

Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases

Feneberg, E., Steinacker, P., Lehnert, S., Schneider, A., Walther, P., Thal, D. R., Linsenmeier, M., Ludolph, A. C., & Otto, M. (2014) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.3109/21678421.2014.905606 · Cited by 156

Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis

Boylan, K., Glass, J. D., Crook, J. E., Yang, C., Thomas, C. S., Desaro, P., Johnston, A., Overstreet, K., Kelly, C. M., Polak, M. A., et al. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-303768 · Cited by 156

Biological Marker Candidates of Alzheimer's Disease in Blood, Plasma, and Serum

Schneider, P., Hampel, H. J., & Büerger, K. (2009) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2009.00104.x · Cited by 154

Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial

Study, T. A. D. C., Grundman, M., Sencakova, D., Jack, C. R., Petersen, R. C., Kim, H. T., Schultz, A. N., Weiner, M., DeCarli, C. S., DeKosky, S. T., et al. (2002) · Journal of Molecular Neuroscience · doi:10.1007/s12031-002-0006-6 · Cited by 153

Impaired Structural Motor Connectome in Amyotrophic Lateral Sclerosis

Verstraete, E., Veldink, J. H., Mandl, R. C. W., van den Berg, L. H., & van den Heuvel, M. P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024239 · Cited by 152

Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS

Ganesalingam, J., An, J., Shaw, C. E., Shaw, G., Lacomis, D., & Bowser, R. P. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07224.x · Cited by 151

Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression

Tortelli, R., Ruggieri, M., Cortese, R., D’Errico, E., Capozzo, R., Leo, A., Mastrapasqua, M., Zoccolella, S., Leante, R., Livrea, P., et al. (2012) · European Journal of Neurology · doi:10.1111/j.1468-1331.2012.03777.x · Cited by 151

Structural MRI reveals cortical thinning in amyotrophic lateral sclerosis

Verstraete, E., Veldink, J. H., Hendrikse, J., Schelhaas, H. J., van den Heuvel, M. P., & van den Berg, L. H. (2011) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-300909 · Cited by 151

Enlarged Substantia Nigra Hyperechogenicity and Risk for Parkinson Disease

Berg, D. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.141 · Cited by 149

A review of the use of magnetic resonance imaging in Parkinson’s disease

Pyatigorskaya, N., Galléa, C., García-Lorenzo, D., Vidailhet, M., & Lehéricy, S. (2013) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285613511507 · Cited by 147

Clinical Utility and Analytical Challenges in Measurement of Cerebrospinal Fluid Amyloid-β1–42 and τ Proteins as Alzheimer Disease Biomarkers

Kang, J., Korecka, M., Toledo, J. B., Trojanowski, J. Q., & Shaw, L. M. J. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2013.202937 · Cited by 147

Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer’s disease

Kadir, A., Marutle, A., Gonzalez, D., Schöll, M., Almkvist, O., Mousavi, M. T., Mustafiz, T., Darreh‐Shori, T., Nennesmo, I., & Nordberg, A. K. (2010) · Brain · doi:10.1093/brain/awq349 · Cited by 145

Longitudinal evaluation of cerebral morphological changes in Parkinson's disease with and without dementia

Ramírez‐Ruiz, B., Martı́, M. J., Tolosa, E., Bartrés‐Faz, D., Summerfield, C., Salgado‐Pineda, P., Gómez‐Ansón, B., & Junqué, C. (2005) · Journal of Neurology · doi:10.1007/s00415-005-0864-2 · Cited by 144

Autoantibodies to amyloid-? and Alzheimer's disease

Hyman, B. T., Smith, C. R., Buldyrev, I., Whelan, C. M., Brown, H., Tang, M., & Mayeux, R. P. (2001) · Annals of Neurology · doi:10.1002/ana.1061 · Cited by 144

Three-dimensional surface mapping of hippocampal atrophy progression from MCI to AD and over normal aging as assessed using voxel-based morphometry

Chételat, G., Fouquet, M., Kalpouzos, G., Denghien, I., De la Sayette, V., Viader, F., Mézenge, F., Landeau, B., Baron, J. C., Eustache, F., et al. (2008) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2007.11.037 · Cited by 143

Electrical impedance myography as a biomarker to assess ALS progression

Rutkove, S. B., Caress, J. B., Cartwright, M. S., Burns, T. M., Warder, J., David, W. S., Goyal, N., Maragakis, N. J., Clawson, L., Benatar, M. G., et al. (2012) · Amyotrophic Lateral Sclerosis · doi:10.3109/17482968.2012.688837 · Cited by 143

Grey matter correlates of clinical variables in amyotrophic lateral sclerosis (ALS): a neuroimaging study of ALS motor phenotype heterogeneity and cortical focality

Bede, P., Bokde, A. L. W., Elamin, M., Byrne, S., McLaughlin, R. L., Jordan, N., Hampel, H. J., Gallagher, L. B., Lynch, C. M., Fagan, A. J., et al. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-302674 · Cited by 141

Multipoint incremental motor unit number estimation as an outcome measure in ALS

Shefner, J. M., Watson, M. L., Simionescu, L. E., Caress, J. B., Burns, T. M., Maragakis, N. J., Benatar, M. G., David, W. S., Sharma, K. R., & Rutkove, S. B. (2011) · Neurology · doi:10.1212/wnl.0b013e318225aabf · Cited by 139

CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large‐scale international multicenter study

Ewers, M., Mattsson, N., Minthon, L., Molinuevo, J. L., Antonell, A., Popp, J., Jessen, F., Herukka, S., Soininen, H., Maetzler, W., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.12.006 · Cited by 133

Dopamine transporter imaging is associated with long‐term outcomes in Parkinson's disease

Ravina, B. M., MAREK, K. L., Eberly, S. W., Oakes, D., Kurlan, R., Ascherio, A., Beal, F. M., Beck, J. C., Flagg, E., Galpern, W. R., et al. (2012) · Movement Disorders · doi:10.1002/mds.25157 · Cited by 133

Structural brain network imaging shows expanding disconnection of the motor system in amyotrophic lateral sclerosis

Verstraete, E., Veldink, J. H., van den Berg, L. H., & van den Heuvel, M. P. (2013) · Human Brain Mapping · doi:10.1002/hbm.22258 · Cited by 132

A blinded international study on the reliability of genetic testing for GGGGCC-repeat expansions in C9orf72 reveals marked differences in results among 14 laboratories

Akimoto, C., Volk, A. E., van Blitterswijk, M., den Broeck, M. V., Leblond, C. S., Lumbroso, S., Camu, W., Neitzel, B., Onodera, O., van Rheenen, W., et al. (2014) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2014-102360 · Cited by 131

Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm

Chiotis, K., Saint‐Aubert, L., Savitcheva, I., Jelić, V., Andersen, P., Jonasson, M., Eriksson, J., Lubberink, M., Almkvist, O., Wall, A. E., et al. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3363-z · Cited by 131

[18F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease

Harada, R., Okamura, N., Furumoto, S., Furukawa, K., Ishiki, A., Tomita, N., Hiraoka, K., Watanuki, S., Shidahara, M., Miyake, M., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3035-4 · Cited by 128

Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF‐H) in blood of ALS model rodents and ALS patients: evaluation of blood pNF‐H as a potential ALS biomarker

Boylan, K., Yang, C., Crook, J. E., Overstreet, K., Heckman, M. G., Wang, Y., Borchelt, D., & Shaw, G. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06386.x · Cited by 121

Concordance Between Cerebrospinal Fluid Biomarkers and [11C]PIB PET in a Memory Clinic Cohort

Zwan, M. D., van Harten, A. C., Ossenkoppele, R., Bouwman, F. H., Teunissen, C. E., Adriaanse, S. F., Lammertsma, A. A., Scheltens, P., van Berckel, B. N. M., & van der Flier, W. M. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132561 · Cited by 120

Virus‐delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis

Miller, T. M., Kaspar, B. K., Kops, G. J. P. L., Yamanaka, K., Christian, L. J., Gage, F. H., & Cleveland, D. W. (2005) · Annals of Neurology · doi:10.1002/ana.20453 · Cited by 120

Utility of axial and radial diffusivity from diffusion tensor MRI as markers of neurodegeneration in amyotrophic lateral sclerosis

Metwalli, N. S., Benatar, M. G., Nair, G., Usher, S., Hu, X. P., & Carew, J. D. (2010) · Brain Research · doi:10.1016/j.brainres.2010.05.067 · Cited by 119

Low-grade systemic inflammation in patients with amyotrophic lateral sclerosis

Keizman, D., Rogowski, O., Berliner, S. A., Ish‐Shalom, M., Maimon, N., Nefussy, B., Artamonov, I., & Drory, V. E. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2008.01112.x · Cited by 118

In Vivo Fibrillar β-Amyloid Detected Using [11C]PiB Positron Emission Tomography and Neuropathologic Assessment in Older Adults

Sojkova, J., Driscoll, I. F., Iacono, D., Zhou, Y., Codispoti, K.-E., Kraut, M. A., Ferrucci, L., Pletniková, O., Mathis, C. A., Klunk, W. E., et al. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.357 · Cited by 113

CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease

Liu, C., Cholerton, B., Shi, M. Y., Ginghină, C., Cain, K. C., Auinger, P., & Zhang, J. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.12.027 · Cited by 113

Elevated CSF TDP-43 levels in amyotrophic lateral sclerosis: Specificity, sensitivity, and a possible prognostic value

Noto, Y., Shibuya, K., Sato, Y., Kanai, K., Misawa, S., Sawai, S., Mori, M., Uchiyama, T., Isose, S., Nasu, S., et al. (2010) · Amyotrophic Lateral Sclerosis · doi:10.3109/17482968.2010.541263 · Cited by 113

SOD1 in Cerebral Spinal Fluid as a Pharmacodynamic Marker for Antisense Oligonucleotide Therapy

Winer, L. K., Srinivasan, D., Chun, S. J., Lacomis, D., Jaffa, M., Fagan, A. M., Holtzman, D. M., Wancewicz, E. V., Bennett, C. F., Bowser, R. P., et al. (2012) · JAMA Neurology · doi:10.1001/jamaneurol.2013.593 · Cited by 113

Differential neuroimmune markers to the onset of Alzheimer's disease neurodegeneration and dementia: Autoantibodies to Aβ(25–35) oligomers, S100b and neurotransmitters

Алексеевна, Г. М., Davidova, T. B., Mališauskas, M., Sewell, R. D. E., Voskresenskaya, N. I., Wilhelm, K., Elistratova, E. I., Sherstnev, V. V., & Morozova‐Roche, L. A. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2007.03.023 · Cited by 112

Uric acid levels predict survival in men with amyotrophic lateral sclerosis

Paganoni, S., Zhang, M., Zárate, A. Q., Jaffa, M., Yu, H., Cudkowicz, M., & Wills, A.-M. A. (2012) · Journal of Neurology · doi:10.1007/s00415-012-6440-7 · Cited by 112

Isolation of Exosomes for Subsequent mRNA, MicroRNA, and Protein Profiling

Rani, S., O’Brien, K., Kelleher, F. C., Corcoran, C., Germano, S., Radomski, M. W., Crown, J. P., & O’Driscoll, L. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-289-2_13 · Cited by 111

The NINDS Parkinson's disease biomarkers program

Rosenthal, L. S., Drake, D. F., Alcalay, R. N., Babcock, D., Bowman, F. D., Chen‐Plotkin, A. S., Dawson, T. M., Dewey, R. B., German, D. C., Huang, X., et al. (2015) · Movement Disorders · doi:10.1002/mds.26438 · Cited by 111

Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer’s disease pathology

Harada, R., Okamura, N., Furumoto, S., Tago, T., Maruyama, M., Higuchi, M., Yoshikawa, T., Arai, H., Iwata, R., Kudo, Y., et al. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2261-2 · Cited by 111

PET Quantification of Tau Pathology in Human Brain with 11C-PBB3

Kimura, Y., Ichise, M., Ito, H., Shimada, H., Ikoma, Y., Seki, C., Takano, H., Kitamura, S., Shinotoh, H., Kawamura, K., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.160127 · Cited by 111

Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS

Oeckl, P., Jardel, C., Salachas, F., Lamari, F., Andersen, P. M., Bowser, R. P., de Carvalho, M. A., Costa, J., Damme, P. V., Gray, E., et al. (2016) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.3109/21678421.2016.1167913 · Cited by 108

Metabolomic analysis of serum by (1) H NMR spectroscopy in amyotrophic lateral sclerosis

Kumar, A., Bala, L., Kalita, J., Misra, U. K., Singh, R. L., Khetrapal, C. L., & Babu, G. N. (2010) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.01.016 · Cited by 107

Cerebellar c9RAN proteins associate with clinical and neuropathological characteristics of C9ORF72 repeat expansion carriers

Gendron, T. F., van Blitterswijk, M., Bieniek, K. F., Daughrity, L. M., Jiang, J., Rush, B. K., Pedraza, O., Lucas, J. A., Murray, M. E., Desaro, P., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1474-4 · Cited by 106

Three-dimensional Patterns of Hippocampal Atrophy in Mild Cognitive Impairment

Becker, J. T. (2006) · Archives of Neurology · doi:10.1001/archneur.63.1.97 · Cited by 106

Cortical thickness in ALS: towards a marker for upper motor neuron involvement

Walhout, R., Westeneng, H., Verstraete, E., Hendrikse, J., Veldink, J. H., van den Heuvel, M. P., & van den Berg, L. H. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-306839 · Cited by 106

18 F-FDG-PET correlates of cognitive impairment in ALS

Canosa, A., Pagani, M., Cistaro, A., Montuschi, A., Iazzolino, B., Fania, P., Cammarosano, S., Ilardi, A., Moglia, C., Calvo, A., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000002242 · Cited by 103

Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study

Lu, C., Petzold, A., Topping, J., Allen, K., Macdonald-Wallis, C. M., Clarke, J., Pearce, N. E., Kühle, J., Giovannoni, G., Fratta, P., et al. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-307672 · Cited by 102

Serum Urate and the Risk of Parkinson's Disease: Results From a Meta-Analysis

Shen, C., Guo, Y. C., Luo, W. F., Chen, L., & Ding, M. (2013) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100012981 · Cited by 100

In vivo mapping of amyloid toxicity in Alzheimer disease

Frisoni, G. B., Lorenzi, M., Caroli, A., Kemppainen, N. M., Någren, K., & Rinne, J. O. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a2e896 · Cited by 97

Hippocampal atrophy and EEG markers in subjects with mild cognitive impairment

Moretti, D. V., Miniussi, C., Frisoni, G. B., Geroldi, C., Zanetti, O. O., Binetti, G. G., & Rossini, P. M. (2007) · Clinical Neurophysiology · doi:10.1016/j.clinph.2007.09.059 · Cited by 97

Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum

Süßmuth, S. D., Tumani, H., Ecker, D., & Ludolph, A. C. (2003) · Neuroscience Letters · doi:10.1016/j.neulet.2003.09.018 · Cited by 96

Soluble multimeric Alzheimer β(1–40) pre-amyloid complexes in dilute solution

LeVine, H. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00052-g · Cited by 95

Extracellular RNAs: development as biomarkers of human disease

Quinn, J. F., Patel, T. C., Wong, D. T., Das, S., Freedman, J. E., Laurent, L. C., Carter, B. S., Hochberg, F. H., Keuren‐Jensen, K. R. V., Huentelman, M. J., et al. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.27495 · Cited by 92

Amyloid-β Immunotherapy for Alzheimers Disease

Fu, H., Liu, B., Frost, J. L., & Lemere, C. A. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710791012017 · Cited by 92

Metabolomics in Cerebrospinal Fluid of Patients with Amyotrophic Lateral Sclerosis: An Untargeted Approach via High-Resolution Mass Spectrometry

Blasco, H., Corcia, P., Pradat, P., Bocca, C., Gordon, P. H., Veyrat‐Durebex, C., Mavel, S., Nadal‐Desbarats, L., Moreau, C., Devos, D., et al. (2013) · Journal of Proteome Research · doi:10.1021/pr400376e · Cited by 92

Plasma biomarkers associated with ALS and their relationship to iron homeostasis

Mitchell, R. M., Simmons, Z., Beard, J. L., Stephens, H., & Connor, J. R. (2010) · Muscle & Nerve · doi:10.1002/mus.21625 · Cited by 91

Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics

Lawton, K. A., Brown, M. V., Alexander, D. C., Li, Z., Wulff, J. E., Lawson, R. J., Jaffa, M., Milburn, M., Ryals, J. A., Bowser, R. P., et al. (2014) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.3109/21678421.2014.908311 · Cited by 90

Reduced α‐synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity

van Dijk, K. D., Bidinosti, M., Weiss, A., Raijmakers, P., Berendse, H. W., & van de Berg, W. D. J. (2014) · European Journal of Neurology · doi:10.1111/ene.12176 · Cited by 88

Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study

Ikonomović, M. D., Abrahamson, E. E., Price, J. C., Hamilton, R. L., Mathis, C. A., Paljug, W. R., Debnath, M. L., Cohen, A. D., Mizukami, K., DeKosky, S. T., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0943-2 · Cited by 87

TDP-43 plasma levels are higher in amyotrophic lateral sclerosis

Verstraete, E., Kuiperij, H. B., van Blitterswijk, M., Veldink, J. H., Schelhaas, H. J., van den Berg, L. H., & Verbeek, M. M. (2012) · Amyotrophic Lateral Sclerosis · doi:10.3109/17482968.2012.703208 · Cited by 86

Five‐year follow‐up of substantia nigra echogenicity in idiopathic REM sleep behavior disorder

Iranzo, Á., Stockner, H., Serradell, M., Seppi, K., Valldeoriola, F., Frauscher, B., Molinuevo, J. L., Vilaseca, I., Mitterling, T., Gaig, C., et al. (2014) · Movement Disorders · doi:10.1002/mds.26055 · Cited by 86

Roles of Brain Angiotensin II in Cognitive Function and Dementia

Mogi, M., Iwanami, J., & Horiuchi, M. (2012) · International Journal of Hypertension · doi:10.1155/2012/169649 · Cited by 84

Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing

Boland, B., Yu, W. H., Corti, O., Mollereau, B., Henriques, A., Bézard, E., Pastores, G., Rubinsztein, D. C., Nixon, R. A., Duchen, M. R., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.109 · Cited by 566

Molecular mechanisms of ischemia and glutamate excitotoxicity

Neves, D., Salazar, I. L., Almeida, R. D., & Silva, R. M. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121814 · Cited by 233

The Evolving Landscape of Exosomes in Neurodegenerative Diseases: Exosomes Characteristics and a Promising Role in Early Diagnosis

Rastogi, S., Sharma, V., Bharti, P. S., Rani, K., Modi, G. P., Nikolajeff, F. K., & Kumar, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22010440 · Cited by 176

Tauroursodeoxycholic acid: a potential therapeutic tool in neurodegenerative diseases

Khalaf, K., Tornese, P., Cocco, A., & Albanese, A. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00307-z · Cited by 156

Neurodegenerative Disorders of Alzheimer, Parkinsonism, Amyotrophic Lateral Sclerosis and Multiple Sclerosis: An Early Diagnostic Approach for Precision Treatment

Pathak, N., Vimal, S. K., Tandon, I., Agrawal, L., Cao, H., & Bhattacharyya, S. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00800-w · Cited by 152

From Recognition to Remedy: The Significance of Biomarkers in Neurodegenerative Disease Pathology

Toader, C., Dobrin, N., Brehar, F.-M., Popa, C., Covache-Busuioc, R.-A., Glavan, L.-A., Costin, H. P., Bratu, B.-G., Corlatescu, A.-D., Popa, A. A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216119 · Cited by 63

Recent Advances in Biomarkers for Early Diagnosis and Therapeutic Monitoring of Neurodegenerative Diseases: A Systematic Review

Jorige, K. M. A. (2026) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.23202490

For Early Diagnosis of Neurodegenerative Diseases: Acting of Biomarkers

Yao, Y. (2020) · American Journal of Biomedical Science & Research · doi:10.34297/ajbsr.2020.11.001628 · Cited by 2

Biomarkers for Managing Neurodegenerative Diseases

Cheslow, L., Snook, A. E., & Waldman, S. A. (2024) · Biomolecules · doi:10.3390/biom14040398 · Cited by 41

Biomarkers of neurodegenerative disorders： How good are they？

VarunRACHAKONDA, TianHongPAN, & WeiDongLE (2004) · Cell Research